Molecular features of lung adenocarcinoma in young patients

BMC Cancer

Zhen Chen¹  Ke Huang¹  Xiaodong Teng¹  Jing Zhang¹  Qian Shen²  He Cao²  Xiao Teng³  Yanting Yuan⁴  Huisong Luo⁴ 

[1] Department of Pathology, the First Affiliated Hospital, College of Medicine, Zhejiang University;Department of Respiratory Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University;Department of Thoracic Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University;Singlera Genomics Inc.;

关键词: Lung adenocarcinoma;    Young age;    Next-generation sequencing;    Molecular features;   

DOI  :  10.1186/s12885-019-5978-5

来源: DOAJ

【 摘 要 】

Abstract Background Lung cancer in young patients is rare and has unique clinicopathological features. However, the molecular features of lung cancer in these patients are unclear. In this study, we aimed to describe the molecular features and outcomes of lung adenocarcinoma in patients aged ≤35 years. Methods A total of 89 patients aged ≤35 years with pathologically diagnosed lung adenocarcinoma were retrospectively evaluated. Mutations in 59 cancer-associated genes and fusions of ALK and ROS1 were analyzed to understand the molecular features of young patients with lung adenocarcinoma. The clinicopathological characteristics and prognosis of each patient were reviewed. Results Of the 89 young patients, 25 (28.1%) were male, 9 (10.1%) were smokers, and the median age was 32 years (range, 18–35 years). The authors analyzed 59 genes and a total of 6 mutations and 2 fusion genes were detected. These genes were distributed among 60 patients, 12 of which had two or more mutations. ERBB2 mutations were most common (24.7%), followed by EGFR mutation (21.3%), ALK fusion (16.9%), TP53 mutation (9.0%), BRAF mutation (3.4%), PIK3CA mutation (1.1%), CTNNB1 mutation (1.1%), and ROS1 fusion (1.1%). EGFR, ERBB2, and TP53 mutations, gene abnormalities, and ALK fusions all had significant correlations with histopathological differentiation (P < 0.01). ALK fusions and EGFR mutations conferred a significantly worse prognosis than did ERBB2 mutations and tumors that contained no mutations or fusions (P < 0.01). Conclusions The molecular features of lung adenocarcinoma in young patients are different from those of common adenocarcinoma, and the main driver genes are closely correlated with tumor differentiation and prognosis.

【 授权许可】

Unknown